DrugMapper


Trade Names:	CIDOFOVIR VISTIDE
Synonyms:	Anhydrous cidofovir Cidofovir Cidofovir anhydrous Cidofovir dihydrate GS-0504 Hpmpc Hpmpc dihydrate NSC-742135 Vistide
Status:	Approved (1996)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	J05AB12
UNII:	768M1V522C


InChI Key	VWFCHDSQECPREK-LURJTMIESA-N
Smile	Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1
InChI	InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1

Action	Mechanism of Action	Reference
INHIBITOR	Human herpesvirus 1 DNA polymerase inhibitor	PubMed

Mesh Heading	Maximum Phase	Mesh ID	Reference
Cytomegalovirus Retinitis	4	D017726	ClinicalTrials
Cytomegalovirus Infections	3	D003586	ClinicalTrials
Uterine Cervical Dysplasia	2	D002578	ClinicalTrials
Sarcoma	2	D012509	ClinicalTrials
Anus Neoplasms	2	D001005	ClinicalTrials
Papilloma	2	D010212	ClinicalTrials
Infections	2	D007239	ClinicalTrials
Herpes Simplex	1	D006561	ClinicalTrials
Uterine Cervical Neoplasms	1	D002583	ClinicalTrials
Kidney Diseases	1	D007674	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Side effects	Relative Frequency (%)	Labels
Renal and urinary disorders Proteinuria	87.8
Investigations Protein urine present	87.8
Gastrointestinal disorders Nausea	68.7
Gastrointestinal disorders Vomiting	68.7
Investigations Body temperature increased	58.3
Renal and urinary disorders Proteinuria	50.4
Investigations Protein urine present	50.4
General disorders and administration site conditions Asthenia	43.5
Blood and lymphatic system disorders Neutropenia	43.5
Skin and subcutaneous tissue disorders Dermatitis	29.6
Nervous system disorders Headache	29.6
Skin and subcutaneous tissue disorders Rash	29.6
Infections and infestations Infection	27.8
Skin and subcutaneous tissue disorders Alopecia	27.0
Gastrointestinal disorders Diarrhoea	26.1
General disorders and administration site conditions Pain	25.2
Blood and lymphatic system disorders Neutropenia	24.4
Blood and lymphatic system disorders Anaemia	24.3
General disorders and administration site conditions Decreased appetite	22.6
Cardiac disorders Dyspnoea	22.6
General disorders and administration site conditions Chills	21.7
Respiratory, thoracic and mediastinal disorders Cough	19.1
Infections and infestations Candida infection	18.3
Gastrointestinal disorders Oral candidiasis	18.3
Eye disorders Hypotony of eye	17.8
Investigations Body temperature increased	14.1
Infections and infestations Infection	11.9
Infections and infestations Pneumonia	8.89
Cardiac disorders Dyspnoea	8.15
Gastrointestinal disorders Nausea	7.41
Gastrointestinal disorders Vomiting	7.41

System Organ Classification (SOC)

	Relative Frequency (%)
Injury, poisoning and procedural complications	19.82
Renal and urinary disorders	16.67
General disorders and administration site conditions	15.09
Investigations	6.53
Eye disorders	6.31
Infections and infestations	4.95
Respiratory, thoracic and mediastinal disorders	4.73
Metabolism and nutrition disorders	4.28
Nervous system disorders	4.28
Blood and lymphatic system disorders	2.25
Vascular disorders	2.25

CIDOFOVIR


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70